BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 16204724)

  • 1. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.
    Nock BA; Maina T; Béhé M; Nikolopoulou A; Gotthardt M; Schmitt JS; Behr TM; Mäcke HR
    J Nucl Med; 2005 Oct; 46(10):1727-36. PubMed ID: 16204724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours.
    Good S; Walter MA; Waser B; Wang X; Müller-Brand J; Béhé MP; Reubi JC; Maecke HR
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1868-77. PubMed ID: 18509636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetraamine-modified octreotide and octreotate: labeling with 99mTc and preclinical comparison in AR4-2J cells and AR4-2J tumor-bearing mice.
    Nikolopoulou A; Maina T; Sotiriou P; Cordopatis P; Nock BA
    J Pept Sci; 2006 Feb; 12(2):124-31. PubMed ID: 16059963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution, elimination, and renal handling of (99m)technetium-Demogastrin 1.
    Trejtnar F; Laznickova A; Laznicek M; Novy Z; Maina T; Nock BA; Behe M
    Cancer Biother Radiopharm; 2012 Mar; 27(2):169-74. PubMed ID: 22409267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
    von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
    Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs.
    Maina T; Nock BA; Zhang H; Nikolopoulou A; Waser B; Reubi JC; Maecke HR
    J Nucl Med; 2005 May; 46(5):823-30. PubMed ID: 15872357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
    Behr TM; Béhé MP
    Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging.
    Nock B; Nikolopoulou A; Chiotellis E; Loudos G; Maintas D; Reubi JC; Maina T
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):247-58. PubMed ID: 12552343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
    Breeman WA; Fröberg AC; de Blois E; van Gameren A; Melis M; de Jong M; Maina T; Nock BA; Erion JL; Mäcke HR; Krenning EP
    Nucl Med Biol; 2008 Nov; 35(8):839-49. PubMed ID: 19026945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
    Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
    J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin.
    Laverman P; Roosenburg S; Gotthardt M; Park J; Oyen WJ; de Jong M; Hellmich MR; Rutjes FP; van Delft FL; Boerman OC
    Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):386-92. PubMed ID: 17934729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (99m)Tc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice.
    Kaloudi A; Nock BA; Lymperis E; Krenning EP; de Jong M; Maina T
    Nucl Med Biol; 2016 Jun; 43(6):347-54. PubMed ID: 27260775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide.
    Sosabowski JK; Matzow T; Foster JM; Finucane C; Ellison D; Watson SA; Mather SJ
    J Nucl Med; 2009 Dec; 50(12):2082-9. PubMed ID: 19910426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results.
    Maina T; Nikolopoulou A; Stathopoulou E; Galanis AS; Cordopatis P; Nock BA
    Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1804-14. PubMed ID: 17594090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
    Okarvi SM; Al Jammaz I
    Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 99mTc-HYNIC-Gastrin Peptides: Assisted Coordination of 99mTc by Amino Acid Side Chains Results in Improved Performance Both In Vitro and In Vivo.
    King R; Surfraz MB; Finucane C; Biagini SC; Blower PJ; Mather SJ
    J Nucl Med; 2009 Apr; 50(4):591-8. PubMed ID: 19289435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy.
    de Jong M; Bakker WH; Bernard BF; Valkema R; Kwekkeboom DJ; Reubi JC; Srinivasan A; Schmidt M; Krenning EP
    J Nucl Med; 1999 Dec; 40(12):2081-7. PubMed ID: 10616889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma.
    Fröberg AC; de Jong M; Nock BA; Breeman WA; Erion JL; Maina T; Verdijsseldonck M; de Herder WW; van der Lugt A; Kooij PP; Krenning EP
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1265-72. PubMed ID: 19266197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.